S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:CLSD

Clearside Biomedical (CLSD) Stock Price, News & Analysis

$1.70
+0.03 (+1.80%)
(As of 08:39 AM ET)
Today's Range
$1.70
$1.70
50-Day Range
$1.20
$2.02
52-Week Range
$0.65
$2.12
Volume
5,321 shs
Average Volume
346,210 shs
Market Capitalization
$127.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Clearside Biomedical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
184.4% Upside
$4.75 Price Target
Short Interest
Healthy
0.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.23mentions of Clearside Biomedical in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$647,999 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.56) to ($0.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.93 out of 5 stars

Medical Sector

411th out of 939 stocks

Pharmaceutical Preparations Industry

192nd out of 436 stocks

CLSD stock logo

About Clearside Biomedical Stock (NASDAQ:CLSD)

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CLSD Stock Price History

CLSD Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Clearside Biomedical: Q4 Earnings Insights
Preview: Clearside Biomedical's Earnings
Clearside Biomedical, Inc. (CLSD)
CLSD Apr 2024 5.000 call
See More Headlines
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLSD
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+184.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-32,490,000.00
Net Margins
-394.91%
Pretax Margin
-394.91%

Debt

Sales & Book Value

Annual Sales
$8.23 million
Book Value
($0.25) per share

Miscellaneous

Free Float
67,398,000
Market Cap
$124.78 million
Optionable
Optionable
Beta
2.28
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. George M. Lasezkay J.D. (Age 72)
    Pharm.D., Pharma.D., President, CEO & Director
    Comp: $816.4k
  • Mr. Charles A. DeignanMr. Charles A. Deignan (Age 60)
    Chief Financial Officer
    Comp: $536.95k
  • Dr. Thomas A. Ciulla M.B.A. (Age 59)
    M.D., Chairman of Scientific Advisory Board
    Comp: $597.21k
  • Ms. Jenny R. Kobin (Age 57)
    Head of Investor Relations
  • Mr. Rick McElheny
    Vice President of Corporate Development
  • Mr. Rafael V. Andino (Age 59)
    Senior Vice President of Engineering & Manufacturing
  • Ms. Susan L. Coultas Ph.D.
    Chief Clinical Officer
  • Dr. Ngai Hang Chong M.B.A.
    M.D., Chief Medical Officer
  • Mr. Leslie B. Zacks (Age 55)
    Secretary

CLSD Stock Analysis - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings
or view top-rated stocks.

What is Clearside Biomedical's stock price target for 2024?

4 brokers have issued twelve-month price objectives for Clearside Biomedical's stock. Their CLSD share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 184.4% from the stock's current price.
View analysts price targets for CLSD
or view top-rated stocks among Wall Street analysts.

How have CLSD shares performed in 2024?

Clearside Biomedical's stock was trading at $1.17 at the beginning of 2024. Since then, CLSD shares have increased by 42.7% and is now trading at $1.67.
View the best growth stocks for 2024 here
.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 339,900 shares, an increase of 23.4% from the February 29th total of 275,400 shares. Based on an average daily trading volume, of 339,500 shares, the days-to-cover ratio is presently 1.0 days.
View Clearside Biomedical's Short Interest
.

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CLSD earnings forecast
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The business had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.22 million. Clearside Biomedical had a negative net margin of 394.91% and a negative trailing twelve-month return on equity of 533.87%. During the same period in the prior year, the company earned ($0.13) earnings per share.

What other stocks do shareholders of Clearside Biomedical own?
When did Clearside Biomedical IPO?

Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.42%), Vanguard Group Inc. (3.42%), Stifel Financial Corp (0.05%), Simplex Trading LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Ngai Hang Victor Chong, Richard T Burke and Thomas Ciulla.
View institutional ownership trends
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLSD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners